18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
| Status: | Available |
|---|---|
| Conditions: | Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 3/22/2019 |
| Contact: | Susan Becker, RN, BSN, CCRC |
| Email: | Beckers@email.chop.edu |
| Phone: | 267-426-0269 |
Expanded Access Use of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
This purpose of this study is to determine the ability of an
18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET scan to detect a focal lesion of
hyperinsulinism and determine the location in patients with congenital hyperinsulinism,
Beckwith Wiedemann Syndrome and suspected insulinoma. Safety data will be collected.
18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET scan to detect a focal lesion of
hyperinsulinism and determine the location in patients with congenital hyperinsulinism,
Beckwith Wiedemann Syndrome and suspected insulinoma. Safety data will be collected.
Inclusion Criteria:
- Subjects of any age with hyperinsulinemic hypoglycemia, diagnosed by a fasting test
and/or response to glucagon stimulation.
- Subjects who are eligible for pancreatic surgery regardless of prior pancreatic
surgery
Exclusion Criteria:
- Pregnant or lactating females
- Any other major illness or condition that in the investigator's judgment will
substantially increase the risk associated with the subject's participation in this
study
- Subjects who are not a candidate for pancreatic surgery
We found this trial at
1
site
South 34th Street
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
215-590-1000
Principal Investigator: Lisa States, MD
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
